Back to search results
NCT07642908

Striatal and Extra-Striatal Cholinergic Terminal Density in LRRK2-PD Mutation

Recruiting
Not specifiedAges 45+Observational
University of Michigan
~15 participants
Updated 2026-06-11 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Cholinergic Differences Between leucine-rich repeat kinase 2 (LRRK2) Parkinson's disease (PD) and Idiopathic/non-LRRK2 PD (iPD)
Measured over Baseline
+5 more outcomes measured

Conditions

Parkinson Disease

Explore related trials

Parkinson DiseaseLRRK2 Gene

Where it's being run

1 sites across 1 states
Michigan1

Study leadership

  • Prabesh Kanel, PhD · PRINCIPAL_INVESTIGATOR · University of Michigan

Who to contact

Nathan Alexander, BSc
[email protected]
734-998-6894
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Cholinergic Differences Between leucine-rich repeat kinase 2 (LRRK2) Parkinson's disease (PD) and Idiopathic/non-LRRK2 PD (iPD)Baseline

    The cholinergic system changes for people with PD. It is anticipated that LRRK2-PD will demonstrate different cholinergic expression compared to iPD. 18F-fluoroethoxybenzovesamicol (\[18F\]FEOBV) PET scans will be used to measure Vesicular acetylcholine transporter (VAChT). Higher levels of VAChT binding indicate higher levels of acetylcholine in the brain. Lower levels of VAChT binding indicate lower levels of acetylcholine in the brain. VAChT levels will be compared across brain regions for LRRK2 vs iPD.

  • Dopaminergic Differences Between LRRK2-PD and iPDBaseline

    The dopaminergic system changes for people with PD. It is anticipated that LRRK2-PD will demonstrate different dopaminergic expression compared to iPD. N-(3-iodoprop-2E-enyl)-2β-carbomethoxy-3β-(4-methyl-phenyl)nortropane (\[¹¹C\]PE2i) PET scans will be used to measure dopamine transporter (DAT). Higher levels of DAT binding indicate higher levels of dopamine in the brain. Lower levels of DAT binding indicate lower levels of dopamine in the brain. DAT levels will be compared across brain regions for LRRK2 vs iPD.

  • Association of Cholinergic Data With Cognition in LRRK2-PDBaseline

    Association of the global average cholinergic uptake (represented by VAChT uptake) with the global average cognitive z-score of individuals with LRRK2-PD.

  • Association of Cholinergic Data With Postural Instability and Gait Difficulties (PIGD) in LRRK2-PDBaseline

    Association of the global average cholinergic uptake (represented by VAChT uptake) with the global average PIGD score of individuals with LRRK2-PD.

  • Association of Dopaminergic Data With Cognition in LRRK2-PDBaseline

    Association of the global average dopaminergic uptake (represented by DAT uptake) with the global average cognitive z-score of individuals with LRRK2-PD.

  • Association of Dopaminergic Data With PIGD in LRRK2-PDBaseline

    Association of the global average dopaminergic uptake (represented by DAT uptake) with the global average PIGD score of individuals with LRRK2-PD.